Linked Life Data

20493451

Source:http://linkedlifedata.com/resource/pubmed/id/20493451

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2010-5-24
pubmed:abstractText
Androgen deprivation therapy with LHRH agonists is the gold standard in the treatment of metastatic prostate cancer. This treatment leads to decrease the bone mass, thus bone mineral density evaluation is recommended after one year of hormonal treatment to measure bone loss. Bisphosphonate is recommended when metastasis occurred during hormonal resistance phase to reduce bone events. The necessity of preventive treatment and the appropriate schedule is not well established. Long term fracture risk should be ideally evaluated with a CT scan and an MRI. Fragmented and focal radiotherapy is considered as the treatment of choice to decrease localized pain. Metastasis surgery has functional results and should be performed before major neurologic symptoms occur. Metabolic radiotherapy is an option for multifocal bone metastases.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1166-7087
pubmed:author
pubmed:issnType
Print
pubmed:volume
20 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S72-6
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
[How to manage bone metastasis in prostate cancer. A case report].
pubmed:affiliation
Service d'urologie, Hôpital Foch, Rue Worth, Suresnes, France.
pubmed:publicationType
Journal Article, English Abstract, Case Reports